系统炎症反应指数（SIRI）在乳腺癌患者中的预后及临床病理价值：一项荟萃分析。

Prognostic and clinicopathological value of systemic inflammation response index (SIRI) in patients with breast cancer: a meta-analysis.

机构信息

Clinical Laboratory, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, The Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, Huzhou, Zhejiang, China.

出版信息

Ann Med. 2024 Dec;56(1):2337729. doi: 10.1080/07853890.2024.2337729. Epub 2024 Apr 3.

BACKGROUND

Many studies have explored the value of the systemic inflammation response index (SIRI) in predicting the prognosis of patients with breast cancer (BC); however, their findings remain controversial. Consequently, we performed the present meta-analysis to accurately identify the role of SIRI in predicting BC prognosis.

METHODS

PubMed, Embase, Cochrane Library, and Web of Science databases were comprehensively searched between their inception and February 10, 2024. The significance of SIRI in predicting overall survival (OS) and disease-free survival (DFS) in BC patients was analyzed by calculating pooled hazard ratios (HRs) and corresponding 95% confidence intervals (CIs).

RESULTS

Eight articles involving 2,997 patients with BC were enrolled in the present study. According to our combined analysis, a higher SIRI was markedly associated with dismal OS (HR = 2.43, 95%CI = 1.42-4.15, < 0.001) but not poor DFS (HR = 2.59, 95%CI = 0.81-8.24, = 0.107) in patients with BC. Moreover, based on the pooled results, a high SIRI was significantly related to T3-T4 stage (OR = 1.73, 95%CI = 1.40-2.14, < 0.001), N1-N3 stage (OR = 1.61, 95%CI = 1.37-1.91, < 0.001), TNM stage III (OR = 1.63, 95%CI = 1.34-1.98, < 0.001), and poor differentiation (OR = 1.25, 95%CI = 1.02-1.52, = 0.028).

CONCLUSION

According to our results, a high SIRI significantly predicted poor OS in patients with BC. Furthermore, elevated SIRI was also remarkably related to increased tumor size and later BC tumor stage. The SIRI can serve as a novel prognostic biomarker for patients with BC.

背景

许多研究已经探讨了全身炎症反应指数（SIRI）在预测乳腺癌（BC）患者预后中的价值；然而，他们的研究结果仍存在争议。因此，我们进行了本次荟萃分析，以准确确定 SIRI 在预测 BC 预后中的作用。

方法

我们全面检索了 PubMed、Embase、Cochrane 图书馆和 Web of Science 数据库，检索时间从数据库建立至 2024 年 2 月 10 日。通过计算合并的风险比（HR）和相应的 95%置信区间（CI），分析 SIRI 对 BC 患者总生存（OS）和无病生存（DFS）的预测意义。

结果

本研究共纳入了 8 篇涉及 2997 例 BC 患者的文章。根据我们的综合分析，较高的 SIRI 与 BC 患者较差的 OS 显著相关（HR=2.43，95%CI=1.42-4.15， < 0.001），但与较差的 DFS 无关（HR=2.59，95%CI=0.81-8.24， = 0.107）。此外，根据汇总结果，高 SIRI 与 T3-T4 期（OR=1.73，95%CI=1.40-2.14， < 0.001）、N1-N3 期（OR=1.61，95%CI=1.37-1.91， < 0.001）、TNM 期 III 期（OR=1.63，95%CI=1.34-1.98， < 0.001）和低分化（OR=1.25，95%CI=1.02-1.52， = 0.028）显著相关。